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Introduction
 Epstein-Barr Virus (EBV) is of increasing medical importance as 
it is the etiologic agent in various lymphomas and carcinomas [1-2]. It 
is now generally accepted that EBV causes, modifies, or contributes to 
the genesis of more malignancies than any other tumor virus does [3].
 The Interferon Regulatory Factor (IRF) family of transcription 
factors plays pivotal roles in the regulation of multiple facets of host 
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defense system, among which IRF7 is the “master” regulator of type I 
Interferon (IFN-I) response to pathogenic infection [4]. Robust IFN-I 
response during infection requires a positive feedback loop between 
IRF7 and IFN-I [5-6]. Aberrant production of IFN-I, however, is 
associated with autoimmune disorders and malignancies [7-9]. Thus, 
tight regulation of IRF7 is important in balancing the appropriate 
immune response to clear invading pathogens while preventing 
immune-mediated pathogenesis [10].
 IFNs exert their functions through induction of IFN-Stimulated 
Genes (ISGs) via Jak-STAT pathways [11-13]. The IFN-I Jak-STAT 
pathway comprises of IFNAR1/2, Jak1, Tyk2, STAT1/2, and IRF9 
[14]. Following IFN-I binding to IFNARs, signaling via protein 
kinases leads to tyrosine phosphorylation and activation of IFNAR1 
at Y466 [15], Tyk2(Y1054/Y1055) and Jak1(Y1034/Y1035), and then to that 
of STAT1(Y701) and STAT2(Y690 and S287) [16]. The phosphorylated 
STAT1/2 then dimerize and associate with IRF9 to form a complex 
termed interferon-stimulated gene factor 3 (ISGF3). ISGF3 
translocates to the nucleus and binds to the IFN Stimulated Response 
Element (ISRE) to activate the transcription of ISGs [12,17-19]. In 
type II IFN (IFNγ) Jak-STAT pathway, Jak2 is auto phosphorylated at 
Y1007/Y1008 in response to IFNγ, and STAT1 is phosphorylated at both 
Y701 and S727. Phosphorylated STAT1 then forms a homodimer termed 
IFNγ-Activated Factor (GAF), which migrates into the nucleus and 
binds to the IFNγ-Activated Sequence (GAS) to transactivate the 
target ISGs.
 Recent studies have shown that the IFN-I Jak-STAT signaling 
pathway plays a dual role in viral infection. At the early stage of 
infection, robust IFN-I response leads to a potent antiviral activity; 
meanwhile, it facilitates the establishment and maintenance of 
persistent infection by inducing the immune exhaustion program 
[20-21]. Therefore, regulation of IFN signaling is pivotal for persistent 
viruses, as the outcomes not only shape the immune response to 
infection and contribute to the establishment of persistent infection, 
but also affect aspects of host cell proliferation and malignancy. 
Notably, resistance to IFN-mediated antiviral treatment of 
malignancies is a problematic clinical issue, for which the underlying 
mechanism is not fully understood [22-24]. Indeed, viruses have 
developed diverse strategies to counteract IFN (IFN-I and-II) 
Jak-STAT signaling pathways [25-28]. However, only limited 
regulators for the Jak-STAT pathways in mammalians have been 
discovered including the SOCS, SHP, and PIAS families [29-32], 
primarily due to the lack of the application of high throughput screen 
strategies. Most of these regulators were originally identified in 
Drosophila [30].
 To understand how EBV evades IRF7-mediated IFN-I response 
in its latency, in this study, we have performed phosphotyrosine 
proteomics, and found that IFN-I Jak-STAT pathway is impaired 
due to attenuated STAT2 activity. Our results also suggest that 
several other Jak-STAT pathways, including IFN-II Jak-STAT 
pathway, are active in EBV latency.
Ning S and Wang L, J Cancer Biol Treat 2016, 3: 009
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Abstract
 Epstein-Barr Virus (EBV) latent infection is associated with a 
variety of lymphomas and carcinomas. Interferon (IFN) Regulatory 
Factors (IRFs) are a family of transcription factors, among which 
IRF7 is the “master” regulator of type I IFNs (IFN-I) that defends 
against invading viruses. Robust IFN-I responses require a positive 
feedback loop between IRF7 and IFN-I. In recent years, we have 
discovered that IRF7 is significantly induced and activated by the 
principal EBV oncoprotein--Latent Membrane Protein 1 (LMP1); 
however, IRF7 fails to trigger robust IFN-I responses in EBV latency. 
We believe this intriguing finding is critical for EBV latency and 
oncogenesis, yet the underlying mechanism of this paradoxical 
phenomenon remains unclear. It is well known that tyrosine 
phosphorylation of most components of the IFN-I Jak-STAT pathway 
is essential for its signaling transduction. Thus, we have performed 
phosphotyrosine proteomics. We have found that the IFN-I Jak-STAT 
pathway is inactive due to the attenuated STAT2 activity, whereas 
the IFN-II Jak-STAT pathway is constitutively active, in EBV 
latency. We further confirmed these results by immunoblotting. This 
pilot study provides valuable information for the critical question 
regarding how the IRF7-mediated IFN-I response is evaded by 
EBV in its latency, and will prompt us to elucidate the underlying 
mechanisms.
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Materials and Methods
Cell lines
 DG75 (EBV-), Akata (Type I), Namalwa (Type I), Daudi (Type 3 
without LMP1), IB4 (Type 3 LCL), P3HR1 (Type 3 without LMP1), 
and JiJoye (Type 3) cells are human B cell lines. These cells were 
cultured in RPMI1640 medium plus 10% FBS and antibiotics. All cell 
culture supplies were purchased from Life Technologies.
Phosphotyrosine proteomics
 Global profiling of tyrosine phosphorylation associated with EBV 
infection was performed by cell signaling technology. Whole cell 
lysates from IB4 were digested, and phosphorylated peptides were 
enriched with IgG control or the antibody p-Tyr-100 (Catalog # 8954) 
that recognizes the motif XyX. LTQ-Orbitrap-Velos LC-MS/MS was 
performed, and MS/MS spectra were evaluated against Homo sapiens 
FASTA database (NCBI), using SEQUEST 3G and the SORCERER 2 
platform from Sage-N Research (v4.0, Milpitas CA), with a 5% default 
false positive rate to filter the results. Duplicate runs have been 
performed.
Immunoblotting
 Cells were lysed with NP40 lysis buffer, and cell lysates were 
subjected to immunoblotting with the indicated antibodies. Signals 
were detected with an Enhanced Chemiluminescence (ECL) kit 
following the manufacturer’s protocol (Amersham Pharmacia Bio-
tech). Phospho-STAT1(Y701) (catalog # 9171), Phospho-STAT2(Y690) 
(catalog# 4441), and STAT1(catalog # 9172) antibodies were 
purchased from cell signaling technology. LMP1 antibody (CS1-4) 
was from Dako. IRF7 (catalog# SC-74472), STAT2 (catalog # SC-476), 
and GAPDH antibodies were from Santa Cruz.
Results and Discussion
 Tyrosine phosphorylation of almost all the components in both 
the IFN-I/II Jak-STAT pathways including IFN receptors, Jaks, 
Tyk2, and STATs is necessary for signaling transduction upon IFN 
stimulation. Thus, phosphotyrosine proteomics is a powerful tool 
to detect the activity of Jak-STAT pathways [16]. To check if the 
IFN-I and IFN-II Jak-STAT pathways are deregulated in EBV latent 
infection, we have taken phosphotyrosine proteomics to profile 
global tyrosine phosphorylation in the EBV-transformed lympho-
blastoid cell line IB4. As shown in table 1, we detected activating 
tyrosine phosphorylation of STAT1(Y701) and Jak1(Y1034/Y1035) 
(for both IFN-I and IFN-II pathways), as well as IFNGR1(Y304) and 
Jak2(Y1007/Y1008) (for IFN-II pathway only). However, activating 
tyrosine phosphorylation of the other three components in the 
IFN-I JAK-STAT pathway, including IFNAR1(Y466), STAT (Y690) or 
Tyk2(Y1054/Y1055), were not detected. Although IFNGR1(Y304) has 
not yet been documented to be required for activating the IFN-II 
signaling, it has been frequently detected in cancers by Mass 
spectrometry. In addition, our results show that STAT3, STAT4, and 
STAT5 are also active in EBV latency. These results suggest that the 
IFN-I Jak-STAT pathway is inactive, but the IFN-II Jak-STAT pathway 
and probably a few other Jak-STAT pathways are constitutively active, 
in EBV latency.
 Consistent with our findings, EBV LMP1 has been shown to 
negatively regulate Tyk2 phosphorylation and the IFN-I signaling 
[33], and to activate STAT3 and -5 in EBV latency [34-35]. It has 
also been reported that Jak1, STAT1 and STAT3, but not STAT2 
and STAT5, are constitutively tyrosine phosphorylated in LCL cells 
derived from PTLD patients [36], and STAT3 has also been reported 
to be constitutively active in EBV-associated immune competent 
patients [37]. STAT1 and Jak3 phosphorylation and activation are 
triggered by LMP1 [38]. However, Jak3 phosphorylation was not 
detected in our MS high throughput analysis.
 To verify the deregulation of the IFN-I Jak-STAT pathway in EBV 
latency, we analyzed its downstream STAT1/2 activity in EBV- and 
EBV+ cell lines with different latency states, including DG75 (EBV-), 
Akata (Type I), Namalwa (Type I), Daudi (Type 3 without LMP1), 
IB4 (Type 3 LCL), P3HR1 (Type 3 without LMP1), and JiJoye 
(Type 3) cells, in response to IFN treatment or Sendai Virus (SeV) 
infection (Figure 1). Phosphorylation of STAT1/2 was probed with 
specific phospho antibodies. The levels of STAT1 and p-STAT1 
are constitutively high in cell lines with LMP1 (IB4 and JiJoye), but 
p-STAT2 is not readily detected in all tested cell lines (Figure 1). 
After 6 h of treatments, STAT2 activity is still barely detectable (Figure 
1A) or significantly lower (Figure 1B) in IB4 and Jijoye cells which 
express high levels of LMP1. Similar results were obtained for shorter 
time treatments (40 min, data not shown). Namalwa is a special cell 
line which resembles IB4 and JiJoye in response to IFN and SeV 
Component Intensity Tyrosine Site Peptide identified
IFNGR1 274,598 304 Y*VSLITSYQPFSLEK
IFNGR1 280,266 304; 311 Y*VSLITSY*QPFSLEK
STAT1 584,201 701 EAPEPMELDGPKGTGY*IK
STAT3 433,965 539; 539; 539 LLGPGVNY*SGCQITWAK
STAT3 33,177 704 YCRPESQEHPEADPGAAPY*LK
STAT3 80,391 705; 705 YCRPESQEHPEADPGSAAPY*LK
STAT4 1,522,430 693 GDKGY*VPSVFIPISTIR
STAT5A 101,007 683 LGDLSYLIYVFPDRPKDEVFSKY-Y*TPVLAK
STAT5A,B 1,938,120 694; 699 AVDGY*VKPQIK
STAT6 468,441 829 LLLEGQGESGGGSLGAQPLLQP-SHY*GQSGISM#SHMDLR
JAK1 159,479 1030; 1035 AIET*DKEYY*TVKDDRDSPVFWY-APECLM#QSK
JAK1 433,328 1030; 1048 AIET*DKEYYTVKDDRDSPVF-WY*APECLM#QSK
JAK1 584,795 1034 AIETDKEY*YTVKDDRDSPVFWY-APECLMQSK
JAK1 159,479 1034; 1035 AIETDKEY*Y*TVKDDRDSPVFWY-APECLM#QSK
JAK1 159,479 1034; 1043 AIETDKEY*YTVKDDRDS*PVFWY-APECLM#QSK
JAK1 72,091 1035 AIETDKEYY*TVKDDRDSPVFWY-APECLM#QSK
JAK1 73,514 598 THIY*SGTLM#DYKDDEGTSEEK
JAK2 114,887 1007 VLPQDKEY*YKVKEPGESPIFWY-APESLTESK
JAK2 62,639 1008 VLPQDKEYY*K
JAK2 271,716 570 REVGDY*GQLHETEVLLK
Table 1: Deregulated activity of the Jak-STAT pathway components in EBV 
latency program III
Asterisks (*) indicate that the left Y is phosphorylated; pound signs (#) indicate 
oxidized methionine. Sites with underlined fonts indicate that the sites are 
responsible for activation of the corresponding components.
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treatments. In all other EBV-positive cell lines (except Namalwa) that 
do not express LMP1, STAT2 activity is readily detected after treat-
ments. In all cell lines, STAT1 activity is still robust after the prolonged 
treatments (16 h), but STAT2 activity is only detected in Akata, Daudi 
and P3HR1 that do not express LMP1 (Figure 1). This finding is con-
sistent with a previous report, in which STAT2 activity is detected in 
Daudi cells [39]. As a target gene induced by IFN-I Jak-STAT, IRF7 
is generally higher in LMP1-negative cells after prolonged treatment 
with IFN, except IB4 (Figure 1). These observations suggest that 
STAT2 activity is repressed in EBV latency, and that LMP1 plays a key 
role in this event.
 We have provided preliminary observations here showing that 
EBV latent infection down regulates IFN-I Jak-STAT pathways, 
at least by attenuating STAT2 activity. We next will profile STAT2 
regulators and evaluate the potential roles of selected regulators in 
EBV evasion of IRF7-mediated IFN-I response. Deregulation of other 
Jak-STAT pathways also deserves further investigation in the setting 
of EBV latent infection.
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